All In Biotech

Drug Trial Radar · NCT06062420

A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202

A Phase 2, Randomized, Open-label, Platform Study Using a Master Protocol to Evaluate Novel Immunotherapy Combinations as First-Line Treatment in Participants With Recurrent/Metastatic PD-L1 Positive Squamous Cell Carcinoma of the Head and Neck

Last checked: Nov 19, 2026Latest source record: Sep 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 316 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

316

Actual

Start

Nov 14, 2023

Primary completion

Sep 10, 2026

Study completion Dec 31, 2027

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
Collaborators
iTeos Therapeutics
First posted
Oct 2, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary purpose of the study is to evaluate the antitumor activity and safety of novel immunotherapy combinations compared with dostarlimab in participants with Programmed death ligand 1 (PD-L1) positive Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC).

Conditions

  • Neoplasms, Head and Neck

Interventions

  • DostarlimabDrug

    Dostarlimab will be administered.

  • BelrestotugDrug

    Belrestotug will be administered.

  • NelistotugDrug

    Nelistotug will be administered.

  • RemzistotugDrug

    Remzistotug will be administered.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Confirmed Objective Response Rate (ORR) compared between Sub studies and Dostarlimab monotherapyTime frame: Up to approximately 24 months

Locations

108 sites in 20 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    New Haven, Connecticut

  • GSK Investigational Site

    Iowa City, Iowa

  • GSK Investigational Site

    St Louis, Missouri

  • GSK Investigational Site

    Columbus, Ohio

  • GSK Investigational Site

    Milwaukee, Wisconsin

  • GSK Investigational Site

    Buenos Aires, Argentina

  • GSK Investigational Site

    Capital Federal, Argentina

  • GSK Investigational Site

    Ciudad Autonoma de Bueno, Argentina

  • GSK Investigational Site

    Córdoba, Argentina

  • GSK Investigational Site

    Florida, Argentina

  • GSK Investigational Site

    Mendoza, Argentina

  • GSK Investigational Site

    San Juan, Argentina

  • GSK Investigational Site

    Santa Fe, Argentina

  • GSK Investigational Site

    Santo André, Brazil

  • GSK Investigational Site

    São Paulo, Brazil

  • GSK Investigational Site

    São Paulo, Brazil

  • GSK Investigational Site

    Calgary, Alberta, Canada

  • GSK Investigational Site

    Edmonton, Alberta, Canada

  • GSK Investigational Site

    Toronto, Ontario, Canada

  • GSK Investigational Site

    Toronto, Ontario, Canada

  • GSK Investigational Site

    Montreal, Quebec, Canada

  • GSK Investigational Site

    Herlev, Denmark

  • GSK Investigational Site

    Turku, Finland

  • GSK Investigational Site

    Bordeaux, France

  • GSK Investigational Site

    Caen, France

  • GSK Investigational Site

    Marseille, France

  • GSK Investigational Site

    Paris, France

  • GSK Investigational Site

    Rouen, France

  • GSK Investigational Site

    Villejuif, France

  • GSK Investigational Site

    Aachen, Germany

  • GSK Investigational Site

    Berlin, Germany

  • GSK Investigational Site

    Giessen, Germany

  • GSK Investigational Site

    Hamburg, Germany

  • GSK Investigational Site

    Regensburg, Germany

  • GSK Investigational Site

    Ulm, Germany

  • GSK Investigational Site

    Frankfurt am Main, Hesse, Germany

  • GSK Investigational Site

    Essen, North Rhine-Westphalia, Germany

  • GSK Investigational Site

    Haidari - Athens, Greece

  • GSK Investigational Site

    Marousi, Greece

  • GSK Investigational Site

    Panórama, Central Macedonia, Greece

Showing 40 of 108 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.